Phaseline

Targets › CLIND

CLIND: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Gastroenterology; next expected readout Jun 2027.

Open in Phaseline: the race on CLIND, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Spaarne GasthuisGentamicin
Bacterial 70S ribosome inhibitor
GENT, CLINDPhase 3Complicated AppendicitisJun 2027

Conditions

Complicated Appendicitis (1)

Modalities

small molecule (1)

Companies

Spaarne Gasthuis (1)

Related targets

GENT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.